The membrane as a target for controlling hypervirulent Clostridium difficile infections
- PMID: 23264511
- PMCID: PMC3695663
- DOI: 10.1093/jac/dks493
The membrane as a target for controlling hypervirulent Clostridium difficile infections
Abstract
Objectives: The stationary phase of Clostridium difficile, which is primarily responsible for diarrhoeal symptoms, is refractory to antibiotic killing. We investigated whether disrupting the functions of the clostridial membrane is an approach to control C. difficile infections by promptly removing growing and non-growing cells.
Methods: The bactericidal activities of various membrane-active agents were determined against C. difficile logarithmic-phase and stationary-phase cultures and compared with known antibiotics. Their effects on the synthesis of ATP, toxins A/B and sporulation were also determined. The effect of rodent caecal contents on anti-difficile activities was examined using two reutericyclin lead compounds, clofazimine, daptomycin and other comparator antibiotics.
Results: Most membrane-active agents and partially daptomycin showed concentration-dependent killing of both logarithmic-phase and stationary-phase cultures. The exposure of cells to compounds at their MBC resulted in a rapid loss of viability with concomitant reductions in cellular ATP, toxins A/B and spore numbers. With the exception of nisin, these effects were not due to membrane pore formation. Interestingly, the activity of the proton ionophore nigericin significantly increased as the growth of C. difficile decreased, suggesting the importance of the proton gradient to the survival of non-growing cells. The activities of the lipophilic antimicrobials reutericyclins and clofazimine were reduced by caecal contents.
Conclusions: These findings indicate that C. difficile is uniquely susceptible to killing by molecules affecting its membrane function and bioenergetics, indicating that the clostridial membrane is a novel antimicrobial target for agents to alleviate the burden of C. difficile infections.
Figures



Similar articles
-
Reutericyclin and related analogues kill stationary phase Clostridium difficile at achievable colonic concentrations.J Antimicrob Chemother. 2011 Aug;66(8):1773-6. doi: 10.1093/jac/dkr201. Epub 2011 May 31. J Antimicrob Chemother. 2011. PMID: 21632577 Free PMC article.
-
Repurposing a platelet aggregation inhibitor ticagrelor as an antimicrobial against Clostridioides difficile.Sci Rep. 2020 Apr 16;10(1):6497. doi: 10.1038/s41598-020-63199-x. Sci Rep. 2020. PMID: 32300130 Free PMC article.
-
Fidaxomicin inhibits spore production in Clostridium difficile.Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S162-9. doi: 10.1093/cid/cis453. Clin Infect Dis. 2012. PMID: 22752866 Free PMC article.
-
Ridinilazole: a novel therapy for Clostridium difficile infection.Int J Antimicrob Agents. 2016 Aug;48(2):137-43. doi: 10.1016/j.ijantimicag.2016.04.026. Epub 2016 May 30. Int J Antimicrob Agents. 2016. PMID: 27283730 Review.
-
Bacteriophage endolysins as a potential weapon to combat Clostridioides difficile infection.Gut Microbes. 2020 Nov 9;12(1):1813533. doi: 10.1080/19490976.2020.1813533. Gut Microbes. 2020. PMID: 32985336 Free PMC article. Review.
Cited by
-
Proteomic Adaptation of Clostridioides difficile to Treatment with the Antimicrobial Peptide Nisin.Cells. 2021 Feb 11;10(2):372. doi: 10.3390/cells10020372. Cells. 2021. PMID: 33670309 Free PMC article.
-
A curated C. difficile strain 630 metabolic network: prediction of essential targets and inhibitors.BMC Syst Biol. 2014 Oct 15;8:117. doi: 10.1186/s12918-014-0117-z. BMC Syst Biol. 2014. PMID: 25315994 Free PMC article.
-
Reprofiled anthelmintics abate hypervirulent stationary-phase Clostridium difficile.Sci Rep. 2016 Sep 16;6:33642. doi: 10.1038/srep33642. Sci Rep. 2016. PMID: 27633064 Free PMC article.
-
Chemical genetic analysis of enoxolone inhibition of Clostridioides difficile toxin production reveals adenine deaminase and ATP synthase as antivirulence targets.J Biol Chem. 2024 Nov;300(11):107839. doi: 10.1016/j.jbc.2024.107839. Epub 2024 Sep 27. J Biol Chem. 2024. PMID: 39343002 Free PMC article.
-
Chemical Genomics, Structure Elucidation, and in Vivo Studies of the Marine-Derived Anticlostridial Ecteinamycin.ACS Chem Biol. 2017 Sep 15;12(9):2287-2295. doi: 10.1021/acschembio.7b00388. Epub 2017 Jul 26. ACS Chem Biol. 2017. PMID: 28708379 Free PMC article.
References
-
- Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol. 2009;7:526–36. - PubMed
-
- O'Brien JA, Lahue BJ, Caro JJ, et al. The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences. Infect Control Hosp Epidemiol. 2007;28:1219–7. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases